Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03236207 · ClinicalTrials.gov registry record · NA

Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula

A NA study of Cow Milk Allergy, sponsored by Société des Produits Nestlé (SPN).

Completed
Registry status
NA
Development phase
67
Enrollment target
12
Study locations

NCT03236207 is a NA study of Cow Milk Allergy that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 67 participants. The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03236207, a NA study of Cow Milk Allergy, has completed, sponsored by Société des Produits Nestlé (SPN).

COMPLETED
Registry status
NA
Development phase
67 participants
Enrollment target
12
Study locations

Study Summary

Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days.

Conditions Studied

Interventions

  • OTHER Test extensively hydrolyzed formula
  • OTHER Control extensively hydrolyzed formula

Study Locations (12)

California

  • Hoag Medical Group - Huntington Beach
  • Stanford University - Mountain View

New York

  • Northwell Health System - Great Neck
  • Icahn School of Medicine at Mount Sinai - New York

Texas

  • Houston Clinical Research Associates - Houston
  • Allergy Asthma Research Institute - Waco

Minnesota

  • Clinical Research Institute - Plymouth

Missouri

  • Midwest Clinical Research - St Louis

New Mexico

  • Breathe America - Albuquerque

Oklahoma

  • Allergy, Asthma and Clinical Research Center - Oklahoma City

South Carolina

  • Carolina ENT - Orangeburg

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2017-07-06
Est. Completion 2018-11-06
Phase NA

What the Registry Record Tells You About NCT03236207

The ClinicalTrials.gov registry entry for NCT03236207 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Société des Produits Nestlé (SPN), which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cow Milk Allergy appearing as the primary indexed condition, and to 2 interventions - of which Test extensively hydrolyzed formula is the first listed.

NCT03236207 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT03236207 about?

NCT03236207 is a clinical study titled "Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula". Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days...

What is the current status of trial NCT03236207?

This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2017-07-06. Estimated completion is 2018-11-06.

What conditions does trial NCT03236207 study?

This clinical trial studies the following conditions: Cow Milk Allergy.

What interventions are being tested in trial NCT03236207?

The interventions under investigation include: Test extensively hydrolyzed formula (OTHER), Control extensively hydrolyzed formula (OTHER).

Who is sponsoring clinical trial NCT03236207?

This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03236207 being conducted?

This trial has 12 study locations across California, Minnesota, Missouri, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.